Publication | Closed Access

Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial

Lymphoid NeoplasiaOncologyMantle-cell LymphomasPathologyRelapsed IndolentRituximab Versus FludarabinePharmacotherapyCancer TreatmentImmunotherapyMedicineRadiation Oncology